Apyx Medical reports preliminary Q4 rev $14.2-14.6M (+13-16% YoY); FY rev $51.9-52.3M (+17-18%)

Apyx Medical Corp

2023-FY EPS reported -$0.54 revenue$52,349,000

Total Q4 revenue $14.2-14.6M, growth 13-16% YoY; Advanced Energy $11.9-12.3M (+12-16%).
Full year total revenue $51.9-52.3M (+17-18%); Advanced Energy $43.1-43.5M (+17-18%); OEM $8.8M (+14%).
CEO says sales softer than expected due to challenging macro environment in cosmetic surgery market; slower new customer adoption.
Company plans to release full Q4 and FY 2023 results in March 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apyx Medical Corp reported the fourth quarter ended December 31, 2023 results: revenue $14.2 to $14.6 million.

Period: the fourth quarter ended December 31, 2023
Revenue: $14.2 to $14.6 million
Result: preliminary results

Exact text from the filing

Total revenue in a range of $14.2 to $14.6 million, representing growth of 13% to 16% year-over-year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apyx Medical Corp reported the year ended December 31, 2023 results: revenue $51.9 to $52.3 million.

Period: the year ended December 31, 2023
Revenue: $51.9 to $52.3 million
Result: preliminary results

Exact text from the filing

Total revenue in a range of $51.9 to $52.3 million, representing growth of 17% to 18% year-over-year.

View on SEC.gov

Browse all earnings releases →

Apyx Medical Corp filing history →

Source: SEC EDGAR

accession 0000719135-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.